All Outputs (27)

Short-term risk of cardiovascular events in people newly diagnosed with gout (2024)
Journal Article
Cipolletta, E., Nakafero, G., Richette, P., Avery, A. J., Mamas, M. A., Tata, L. J., & Abhishek, A. (2024). Short-term risk of cardiovascular events in people newly diagnosed with gout. Arthritis and Rheumatology, https://doi.org/10.1002/art.42986

Objectives
To investigate the temporal association between first diagnosis of gout and cardiovascular events in the short-term.

Methods
We performed a self-controlled case series analysis and a cohort study using data from linked primary care, h... Read More about Short-term risk of cardiovascular events in people newly diagnosed with gout.

Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study (2024)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., & Abhishek, A. (2024). Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study. BMJ Open Gastroenterology, 11(1), Article e001370. https://doi.org/10.1136/bmjgast-2024-001370

Objective To investigate (1) the UK-wide inactivated influenza vaccine (IIV) uptake in adults with inflammatory bowel disease (IBD), (2) the association between vaccination against influenza and IBD flare and (3) the effectiveness of IIV in preventin... Read More about Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study.

2023 EULAR classification criteria for hand osteoarthritis (2024)
Journal Article
Haugen, I. K., Felson, D. T., Abhishek, A., Berenbaum, F., Bierma-Zeinstra, S., Dziedzic, K. S., Edwards, J. J., Englund, M., Hermann-Eriksen, M., Herrero-Beaumont, G., Hill, C., Ishimori, M. L., Jonsson, H., Karjalainen, T., Leung, Y. Y., Maheu, E., Mallen, C. D., Marshall, M., Moe, R. H., Ramonda, R., …Kloppenburg, M. (2024). 2023 EULAR classification criteria for hand osteoarthritis. Annals of the Rheumatic Diseases, 83(11), 1428-1435. https://doi.org/10.1136/ard-2023-225073

Objectives The objective of this study is to develop classification criteria for overall hand osteoarthritis (OA), interphalangeal OA and thumb base OA based on self-reported data and radiographic features.

Methods The classification criteria sets... Read More about 2023 EULAR classification criteria for hand osteoarthritis.

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B., & Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article
Fuller, A., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Maxwell, J. R., Bingham, S., Vedhara, K., & Abhishek, A. (in press). Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology, Article keae175. https://doi.org/10.1093/rheumatology/keae175

Objective
To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).

Methods
Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., Abhishek, A., & . (2024). Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study. Rheumatology, Article keae160. https://doi.org/10.1093/rheumatology/keae160

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice (2024)
Journal Article
Mandl, P., D'Agostino, M. A., Navarro-Compán, V., Geßl, I., Sakellariou, G., Abhishek, A., …Filippou, G. (2024). 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Annals of the Rheumatic Diseases, 83, 752-759. https://doi.org/10.1136/ard-2023-224771

Objective: To formulate evidence-based recommendations and overarching principles on the use of imaging in the clinical management of crystal-induced arthropathies (CiAs). Methods: An international task force of 25 rheumatologists, radiologists, meth... Read More about 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Cook, J. A. (2023). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9

Background
Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.

How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey (2023)
Journal Article
Prior, J. A., Roddy, E., Solis-Trapala, I., Cornwall, N., Jinks, C., Abhishek, A., …Hider, S. (2023). How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey. Rheumatology Advances in Practice, 7(3), Article rkad102. https://doi.org/10.1093/rap/rkad102

Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned? (2023)
Journal Article
Cipolletta, E., Moscioni, E., Sirotti, S., Di Battista, J., Abhishek, A., Rozza, D., Zanetti, A., Carrara, G., Scirè, C. A., Grassi, W., Filippou, G., & Filippucci, E. (2024). Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned?. Rheumatology, 63(8), 2205-2212. https://doi.org/10.1093/rheumatology/kead565

Objective

To develop the optimal US scanning protocol for the diagnosis of CPPD disease.

Methods

In this cross-sectional study, consecutive patients with a crystal-proven diagnosis of CPPD disease, and age-, sex-matched disease controls and... Read More about Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned?.

Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study (2023)
Journal Article
Sokhal, B. S., Matetić, A., Abhishek, A., Banerjee, A., Partington, R., Roddy, E., …Mamas, M. A. (2023). Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study. American Journal of Cardiology, 206, 210-218. https://doi.org/10.1016/j.amjcard.2023.08.138

Data are limited on whether the causes of emergency department (ED) encounters for cardiovascular diseases (CVDs) and associated clinical outcomes vary by frailty status. Using the United States Nationwide ED Sample, selected CVD encounters (acute my... Read More about Impact of Frailty on Emergency Department Encounters for Cardiovascular Disease: A Retrospective Cohort Study.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective
Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develo... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective

Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have deve... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (2023). The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Annals of the Rheumatic Diseases, 82(10), 1248-1257. https://doi.org/10.1136/ard-2023-224575

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develop... Read More about The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease (2023)
Journal Article
Cipolletta, E., Abhishek, A., Di Matteo, A., Grassi, W., & Filippucci, E. (2023). Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease. RMD Open, 9(1), Article e002940. https://doi.org/10.1136/rmdopen-2022-002940

Objective To test whether the double contour (DC) sign has a different dynamic behaviour in gout and calcium pyrophosphate deposition (CPPD) and whether the dynamic assessment of the DC sign increases its accuracy in gout diagnosis. Methods This cros... Read More about Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION:
To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare.

METHODS:
Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.